Opdivo plus chemo improves event-free survival in NSCLC patients
Bristol Myers Squibb (BMS) has announced that its PD-1 inhibitor Opdivo (nivolumab) plus chemotherapy improved event-free survival in a Phase III trial in patients w...
Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.
Continue readingExploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.
Continue readingExploring emerging approaches to neurodegenerative disease research and treatment.
Continue readingHighlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement